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ABSTRACT
Objective: To report the clinical presentation, pathological pattern and treatment options of Prostate 
Cancer (PCa) cases diagnosed at Al-Azhar University Hospitals, Cairo, Egypt over the last 30 years.
Patients and Methods: Case sheets and hospital records of 322 consecutive cases of prostate cancer 
(PCa) diagnosed over 30 years period in Al-Azhar University Hospitals (between January 1980 and 
December 2009) were retrospectively analyzed. One fourth of cases presented during the first 15 years 
from 1980 to 1994 (Group I), while the remaining majority were encountered in the following 15 years 
from 1995 to 2009 (Group II). Assessment included Digital Rectal Examination (DRE), Pelvi-Abdominal 
ultrasonography, transrectal ultrasonography (TRUS) guided prostate biopsy. Serum Prostatic Acid 
Phosphatase (PAP) was available for the first group, while Prostate Specific Antigen (PSA) was available 
only in the second group. Cases with advanced disease, pelvi-abdominal Computed Tomography (CT) 
or Magnetic Resonance Imaging (MRI) and bone scan were also performed to assess staging.
Results: The mean age of patients was 66.2±7 years (range 52-85). At disease presentation 90% 
of patients were 60 years or above. Organ confined disease was encountered in 17% and 45% in 
Group I and Group II respectively. Common clinical presentations included Lower Urinary Tract 
Symptoms (LUTS) and urine retention. Radical prostatectomy was done in 4% of Group I and 21% of 
Group II. Most of non organ confined cases were treated by castration. At the end of follow up period 
28.5% of cases were living, while the remaining were dead either because of tumour related causes 
(31%) or non tumour related causes (40%). The mean follow-up period of cases was 40.39 months.
Conclusion: In this cohort of cases from a tertiary care referral hospital, prostatic carcinoma is usually 
diagnosed late. The majority of patients presented with advanced disease where available modalities 
of treatment are still limited. A coordinated awareness program to educate people may be needed. 
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INTRODUCTION                                            
In Egypt, the relative frequency of prostatic 
carcinoma is much lower than elsewhere 
reported as compared to bladder carcinoma.
Difference in genetic predisposition, diet 
and climate added to the rarity of screening 
programs may contribute to the difference 
among other countries. Moreover the low 
male life expectancy in Egypt may be a factor 
behind low occurrence1.
Data about the epidemiology of Prostate 
Cancer (PCa) in Egypt is lacking due to 
public unawareness and scarce provision of 
health care to the disease. This had prompted 
the Egyptian Urological Association (EUA) 
to launch a nation-wide prostate health 
campaign for detection of PCa in Egypt 
during February and March 2001 where 
Prostate adenocarcinoma was encountered in 
1.3% of 5148 cases2. 
Men who seek knowledge about PCa are 
faced with a lack of clarity and consensus 
in some areas, especially with regard to 
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individual risk, perceived risk factors, 
screening and treatment options. Some of 
this uncertainty might likely stem from 
a significant neglect of PCa compared with 
other cancers3.
Herein, we retrospectively examined the 
clinical, pathological features and treatment 
line adopted for prostate cancer cases 
diagnosed in our department over 30 years 
period.
PATIENTS AND METHODS                         
Case sheets and hospital records of 322 
consecutive cases of prostate cancer (PCa) 
diagnosed over 30 years period in Al Azhar 
University Hospitals (between January 1980 
and December 2009) were retrospectively 
analyzed. 
Several features were studied: The age 
of the patients, clinical presentation, DRE, 
clinical stage of the tumors. The patients were 
categorized into two groups based on the date 
of diagnosis. The first group (Group I) included 
72 cases (22%) diagnosed in the first 15 
years (from 1980 to 1994) and the second 
group (Group II) comprised 250 cases 
(78%) diagnosed in the next 15 years (from 







No. % No. % No. %
<60 
years 4 6 30 12 34 11
60-70 
years 42 58 94 38 136 42
>70 
years 26 36 126 50 152 47
Total 72 100 250 100 322 100






No. % No. % No. %
LUTS 13 18 126 50 139 43
Urine 
retention 37 51 76 30 113 35
Distant 
metastasis 9 13 14 6 23 7
Hematuria 1 1.5 9 4 10 3
Incidental 1 1.5 12 5 13 4
Post TURP 11 15 13 5 24 8
Total 72 100 250 100 322 100
Table 2: Clinical presentation of cases
with a mean age of 66.2±7.9 years. Assessment 
included DRE, urine analysis and pelvi-
abdominal ultrasonography, TRUS guided 
prostate biopsy. Serum PAP was used in group I, 
while serum PSA was only available in group II. 
For those with advanced disease pelvi-
abdominal Computed Tomography (CT) or 
Magnetic Resonance Imaging (MRI) and Bone 
scan were performed to assess proper staging.
RESULTS                                                      
The mean age of the patients at diagnosis 
was 66.2±7 years (range 52-85). At disease 
presentation 90 % of patients were 60 
years or above. While most of the patients 
in Group I (58%) were between 60 and 70 
years of age, half of the patients in Group II 
were over 70 years of age (Table 1).
The majority of patients in this study were 
symptomatic. The most common symptoms 
were LUTS and urine retention, while urine 
retention was the most common presentation 
in group I (51%), LUTS was more prevalent 
in group II (50%). Eight percent of cases were 
diagnosed as PCa after TURP. The incidental 
cases were very rare (4%) (Table 2). 
The results of this study showed that 39% 
had organ confined PCa while the remaining 
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No. % No. % No. %
Organ 




58 83 137 55 197 61
Total 72 100 250 100 322 100
Table 3: Clinical stage of cases





No. % No. % No. %
Watchful 
waiting 0 0 7 3 7 2
Radical 
prostatectomy 3 4 53 21 56 17
Surgical 
castration 48 67 115 57 163 51
Medical 
castration 54 72 142 57 196 61
Radiotherapy 8 11 13 5 21 6
Table 4: Treatment modalities done for studied cases
cases had non organ confined disease. There 
was statistically significant increase in the 
number of patients who had organ confined 
disease in Group II (45%) compared to (17%) 
in Group I (Table 3).
Radical prostatectomy was done in 
only 4% of Group I and 21% of Group II. 
The majority of cases in both groups were 
treated by hormonal therapy either as a 
primary or secondary treatment, surgical 
castration was performed in (51%) of cases 
while medical castration was the modality of 
treatment in (61%). Secondary treatment was 
needed in (62%) of cases (Table 4).
Each patient was treated according to 
whether the tumour was organ confined or 
non organ confined. While 100% of cases of 
radical prostatectomy were organ confined, 
all patients who underwent radiotherapy 
were non organ confined (Table 5).
At the time of follow up, 28.5% of cases 
were living either with the disease (22.5%) 
or disease free (6%) and the remaining cases 
were dead either because of the tumour (31%) 
or non tumour related (Table 6).
The mean follow-up period of cases was 
40.39 months (median 29 months) ranging 
from 13-132 months.
DISCUSSION                                                    
Prostate cancer is a very complex disease 
and the decision-making process requires 
the clinician to balance clinical benefits, 
life expectancy, comorbidities and potential 
treatment related side effects. Accurate 
prediction of clinical outcomes may help 
in the difficult process of making decisions 
related to prostate cancer4. The decision to 
treat elderly men with prostate cancer should 
be made based on a thorough assessment 
of life expectancy, patient preference and 
outcome expectations based on pathological 
criteria5.
The mean age at diagnosis (66.2±7 years, 
range 52-85), as well as the peak age incidence 
is comparable to reports from other study6, 
in which median age at diagnosis was 69.9 
(range: 59-93). The youngest patient in this 
study was 52 years old, other researchers7, 
from Nigeria reported PCa in a patient 47 
years old. There was difference between 
the two groups regarding the age of 
presentation. In those cases younger than 
60, 5 % of cases were of Group I compared 
to 12% of Group II. This is due to the 
widespread use of PSA and TRUS biopsy 
in the date beyond 1995 that lead to more 
detection of PCa at younger ages. 
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No. % No. % No. %
Watchful 
waiting 7 6 0 0 7 2
Radical 
prostatectomy 55 44 0 0 55 17
Surgical 
castration 27 22 136 69 163 51
Medical 
castration 49 39 147 76 196 61
Radiotherapy 0 0 21 11 21 6
Table 5: Tumor-stage and treatment modalities 
The most common presentations were 
LUTS and urine retention, while LUTS was 
more prevalent in Group II (50 %), urine 
retention was the most common presentation 
in Group I (51%). These results are comparable 
to the results of other study7, in which the 
majority of cases (87%) presented with LUTS 
and features of locally advanced or metastatic 
disease.
The results of this study showed that 
(39%) of our patients had organ confined 
disease, while the remaining (61%) had non 
organ confined disease. These results were in 
agreement with those reported by El-Nahas 
et al8, who reported (41.7%) organ confined 
disease in their study.
In this study, there was statistically significant 
increase in the number of patients who had 
organ confined disease in Group II (45%) 
compared to only (17%) in Group I. The 
reason for the late presentation in Group I could 
stem from ignorance, marked poverty that 
has permeated our society and that prostate 
cancer is not a health priority exceeded by 
bladder cancer. Other reasons may explain 
the prevalence of non organ confined PCa 
in Group I, such as absence of screening 
program, inadequate diagnostic facilities 
(no wide use of PSA as a tumor marker) and 
lack of health education. 
The majority of cases in both groups were 
treated by hormonal therapy either surgical 
(51%) or medical (61%), These results were 
also in agreement with those reported in 
another study6, who included totally 83 
patients 78% of them were treated by hormonal 
manipulation. Radical prostatectomy was 
done in 4% of Group I and 21% of Group II, 
this was due to the increased number of organ 
confined disease in group II than in Group I. 
Secondary treatment was needed in (62%) 
of cases which was much higher than that 
reported by other studies7, 9, 10 who reported 
secondary treatment in up to 28 % of their 
patients.
Each patient was treated according to 
whether the tumour was organ confined or 
non organ confined. While all cases treated by 
radical prostatectomy were organ confined, 
all patients who underwent radiotherapy 
were non organ confined. The rates of 
radical prostatectomy and radiation therapy 
observed in our study are comparable to those 
observed by other studies11,12, who reported 
radical prostatectomy in 39.7% and 35.5%, 
respectively, while radiation therapy was 
reported in 31.4% and 30.5%, respectively in 
clinically localized prostate cancer. 
Prostate cancer related death rate in our 
study was 31%. In other study in Nigeria the 
rate was 15.6%7, the higher mortality rate 
in our study than theirs was because that, 
the majority of their patients were loss to 
follow up with only 36.9% still attending 
outpatient clinic. In this study 3% of patients 
with organ confined disease died because of 
the tumour, similar results were reported by 
other researchers13, in which 2.7% of cases 
with low and intermediate prostate cancer 
died because of the tumour regardless of 
treatment strategy. 
The mean follow-up period of cases was 
40.39 months (median 29 months) ranging 
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Treatment Organ confined Non organ confined Total
No. % No. % No. %
Living (disease free) 20 16 0 0 20 6
Living with disease 31 25 41 21 72 22.5
Died (tumour related) 4  3 97 49 101 31
Died (tumour non related) 69 55 59 30 128 40
Unknown 1 1 0 0 1 0.5
Total 125 100 197 100 322 100
Table 6: Tumor stage and cause of death 
from 13-132 months. These results were in 
agreement with the results of researchers from 
Egypt14 and from Nigeria7 who followed up 
their patients for 39 and 36 months respectively, 
but it was very short period compared with 
researchers from Europe15, who followed up 
their patients for 10 years.
The primary limitation of this series is the 
retrospective nature of the study. There is the 
potential that patients with unfavorable features 
are not voluntarily reported to the registry, or 
that unfavorable outcomes are inaccurately 
reported. The second limitation is short follow 
up period. The third limitation is that this work 
is coming from single institution which may 
not reflect the exact figures about PCa in our 
country. However, it gives an idea about 
the low incidence of PCa in Egypt, the late 
presentation of this tumor in a considerable 
number of patients and the defective modalities 
of treatment in providing cure for most of cases.
In conclusion; this cohort of cases from a 
tertiary care referral hospital, prostatic carcinoma 
is usually diagnosed late. The majority of 
patients presented with advanced disease where 
available modalities of treatment are still 
limited. A coordinated awareness program to 
educate people may be needed. 
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